Kymera Therapeutics, Inc. (KYMR) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$119.06

From 52W high−7.51%

Volume1.87M

Market cap$9.79B

P/E (TTM)—

P/S (TTM)93.3x

Div yield—

Key dataSep 18, 2026

Open

$119.06

From 52W high

−7.51%

Volume

1.87M

Market cap

$9.79B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−31.4x

P/E (TTM)

—

RSI (14)

51.4

MomentumView details →

1D Return

−0.62%

YTD Return

+50.26%

SummaryUpdated Jun 1, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in August 2020 and has emerged as a pioneer in the field of targeted protein degradation, a novel therapeutic approach that harnesses the body's natural cellular machinery to eliminate disease-causing proteins. Since its inception, Kymera has built a robust pipeline of small molecule protein degraders targeting both oncology and immunology indications, with multiple programs advancing through clinical trials and a strategic partnership with Sanofi for its lead IRAK4 program.

Ask drillr about Kymera Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−31.4x

EV/Sales

87.5x

P/S (TTM)

93.3x

P/B (TTM)

6.5x

ProfitabilityView details →

Gross Margin

101.98%

Net Margin

−285.41%

EBITDA Margin

−278.85%

ROE (TTM)

−19.85%

ROA (TTM)

−18.21%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+134.82%

EPS YoY

+6.34%

FCF YoY

+5.92%

Revenue CAGR 3Y

−5.75%

EPS CAGR 3Y

−23.83%

EBITDA YoY

−9.64%

MomentumView details →

1D Return

−0.62%

YTD Return

+50.26%

1Y Return

+137.98%

RSI (14)

51.4

vs 50D SMA

+2.22%

vs 200D SMA

+28.01%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

9.83x

Quick Ratio

9.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.62

EPS Surprise

12.99%

Beats (12Q)

7/12

Next Q EPS Est

−$1.25

Avg Surprise (4Q)

−6.87%

Rev Surprise

98.32%

Financials snapshotView financials →

Revenue (TTM)

104.99M

Net Income (TTM)

−299.65M

Op. CF (TTM)

−236.76M

Next earningsNov 3, 2026 →

Latest newsMore news →

Kymera Therapeutics announced presentations on KT-621, a first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses.19d ago

Kymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule.46d ago

Similar companies

Nuvalent, Inc.NUVL Krystal Biotech, Inc.KRYS Cytokinetics, IncorporatedCYTK Avidity Biosciences IncRNAM Arrowhead Pharmaceuticals, Inc.ARWR Apogee Therapeutics, Inc.APGE Find similar companies →

Latest newsMore news →

Kymera Therapeutics announced presentations on KT-621, a first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses.19d ago Kymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule.46d ago Kymera Therapeutics reported Q2 2026 financial results with collaboration revenue of $65.0 million, a net loss of $61.2 million, and diluted EPS of -$0.62.47d ago